Last reviewed 2026-04-23 · How we verify

TNM002

TNM002 is a monoclonal antibody targeting PD-1.

TNM002 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.

At a glance

Mechanism of action

TNM002 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing T cell-mediated anti-tumor responses.

Approved indications

• Non-small cell lung cancer, PD-L1 positive

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Rash
• Pyrexia
• Cough
• Dyspnea
• Arthralgia
• Pneumonia
• Pneumonitis

Key clinical trials

• Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers (PHASE2)
• A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine (PHASE1)
• Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (PHASE3)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults (PHASE1)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TNM002 CI brief — competitive landscape report
• TNM002 updates RSS · CI watch RSS
• Zhuhai Trinomab Pharmaceutical Co., Ltd. portfolio CI